TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER (TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER).
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis; electrolytes maintain acid-base balance and cellular function; dextrose provides caloric energy. Sulfite-free formulation reduces risk of allergic reactions.
| Metabolism | Amino acids are metabolized via transamination and deamination pathways; dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are not metabolized but are eliminated via renal excretion. |
| Excretion | Renal excretion of amino acids and dextrose metabolites; virtually 100% renal elimination of infused water and electrolytes. |
| Half-life | Amino acids: 0.5-2 hours; dextrose: 1-2 hours; clinical context: rapid elimination necessitates continuous infusion to maintain nutrient levels. |
| Protein binding | Amino acids: minimal (<10%); dextrose: negligible; no significant binding. |
| Volume of Distribution | Amino acids: 0.3-0.5 L/kg; dextrose: 0.2 L/kg; reflects distribution in total body water. |
| Bioavailability | Intravenous: 100%; not administered via enteral routes. |
| Onset of Action | Intravenous: immediate (within minutes) elevation of plasma amino acid and glucose levels. |
| Duration of Action | Duration: 2-4 hours post-infusion; clinical notes: continuous infusion required for sustained nutritional support. |
Intravenous infusion; dose determined by individual protein and caloric requirements, typically 1.5 to 2.5 g/kg/day of amino acids (equivalent to 35-59 mL/kg/day of TRAVASOL 4.25%) for adults.
| Dosage form | INJECTABLE |
| Renal impairment | In patients with GFR <50 mL/min: reduce amino acid dose to 0.6-1.0 g/kg/day; monitor BUN and electrolyte levels; avoid in severe renal impairment unless on renal replacement therapy. |
| Liver impairment | In Child-Pugh B or C: avoid use due to risk of hepatic encephalopathy from amino acid load; use specialized hepatic formulations if necessary. |
| Pediatric use | Dose based on protein and caloric needs: infants and children typically 2.0-3.0 g/kg/day of amino acids (equivalent to 47-71 mL/kg/day of TRAVASOL 4.25%); adjust for age and clinical condition. |
| Geriatric use | No specific dosage adjustment except based on renal and hepatic function; monitor fluid and electrolyte balance closely due to decreased physiological reserve and higher risk of volume overload. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER (TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER).
| Breastfeeding | Amino acids and dextrose are normal constituents of breast milk. No adverse effects expected. M/P ratio not established; considered compatible with breastfeeding. |
| Teratogenic Risk | No teratogenic effects reported in humans. Travasol (amino acids) and dextrose are essential nutrients; no fetal risk is anticipated when used appropriately. No specific trimester risks identified. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to any component","Severe hyperglycemia or uncontrolled diabetes","Severe electrolyte disorders not corrected","Hepatic coma or severe hepatic impairment","Severe renal failure without dialysis","Phenylketonuria (phenylalanine-containing component)"]
| Precautions | ["Risk of hyperglycemia, particularly in diabetic patients; monitor blood glucose","Electrolyte imbalances; monitor serum electrolytes regularly","Fluid overload; use with caution in patients with heart failure or renal impairment","Sulfite sensitivity; contraindicated in patients with known sulfite allergy (though labeled as sulfite-free)","Infection risk from intravenous catheter","Hepatic steatosis with prolonged use"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal electrolytes, glucose, acid-base status, and renal function. Monitor fetal growth if prolonged administration. Ensure proper IV access and infusion rate. |
| Fertility Effects | No known adverse effects on fertility. Amino acids and dextrose are physiological nutrients; reproductive impact not expected. |